Depth of Response & Stability of Response of Lebrikizumab

0 SAR
Checkout

Overview

In this video, Dr. Naiem T. Issa reviews long-term data from the ADvocate
1, ADvocate 2, and ADjoin studies, highlighting sustained skin clearance
(EASI 90/100), stable monthly maintenance responses, and durable itch
relief with Ebglyss® (lebrikizumab) 250 mg Q4W for up to 3 years in
moderate-to-severe atopic dermatitis. He also shares a real-world case of a
77-year-old patient with longstanding atopic dermatitis, demonstrating
marked improvements in BSA and itch severity after 20 weeks of
lebrikizumab monotherapy, reinforcing its depth and durability of response.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • • Review up to 3-year efficacy data of lebrikizumab 250 mg Q4W, including
    sustained EASI 90/100 responses.
    • Highlight the stability of skin clearance and itch improvement with monthly
    maintenance dosing.
    • Demonstrate real-world effectiveness through a patient case showing
    improvements in BSA and Itch NRS.
    • Reinforce the key message that lebrikizumab delivers deep and durable
    control of moderate-to-severe atopic dermatitis.

     

     

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    PP-LK-SA-0264


Related Classes